1 |
Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial
Seok Jin Kim, Dok Hyun Yoon, Jin Seok Kim, Hye Jin Kang, Hye Won Lee, Hyeon-Seok Eom, Jung Yong Hong, Junhun Cho, Young Hyeh Ko, Jooryung Huh, Woo-Ick Yang, Weon Seo Park, Seung-Sook Lee, Cheolwon Suh, Won Seog Kim
Cancer Res Treat.2020;52(2):374-387. Published online 2019 August 13
DOI: http://dx.doi.org/10.4143/crt.2019.198
|
|
2 |
Brentuximab vedotin: clinical updates and practical guidance
Jun Ho Yi, Seok Jin Kim, Won Seog Kim
Blood Res.2017;52(4):243-253. Published online 2017 December 26
DOI: http://dx.doi.org/10.5045/br.2017.52.4.243
|
|